TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

180 Life Sciences 

Citius Pharmaceuticals

Marathon Digital Holdings

SNDL Inc.

Savara

Zomedica

Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.

7 Reddit Penny Stocks Seeing the Most Chatter Today

LONDON--(BUSINESS WIRE)--Theramex, a global company specialised in women's health, announced today the Decentralised Procedure approval in several EU countries and the UK of BIJUVA® (1 mg estradiol / 100 mg progesterone) capsules for the indication of continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses. "Up to 80% of women experience vasomotor symptoms during their menopau

EU & UK Conclude Decentralised Procedure Approval for Bijuva® (Estradiol & Progesterone) Capsules for Hormone Replacement Therapy

TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q4 2020 Results - Earnings Call Transcript

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50.00% and 6.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) Reports Q4 Loss, Tops Revenue Estimates

Shares of TherapeuticsMD (NASDAQ:TXMD) rose 9.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 21.05% over the past year to ($0.15), which missed the estimate of ($0.10).

Recap: TherapeuticsMD Q4 Earnings

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD net product revenue in 2020 increased 84% over 2019; conference call at 8:30am ET today to discuss financial and business results for 2020.

TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--March Conferences

TherapeuticsMD Announces Participation in Upcoming Investor Conferences

TherapeuticsMD (TXMD) closed the most recent trading day at $1.63, moving +1.24% from the previous trading session.

TherapeuticsMD (TXMD) Outpaces Stock Market Gains: What You Should Know

BOCA RATON, Fla.--(BUSINESS WIRE)--4Q date announcement press release

TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its underwritten public offering of 59,459,460 shares of its common stock for net proceeds of approximately $97.1 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by TherapeuticsMD. All of the shares in the offering were sold by TherapeuticsMD. In addition, TherapeuticsMD has granted the underwriter a 30-day option to purchase up to approxim

TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 59.5 million shares of its common stock for gross proceeds of $110 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by TherapeuticsMD. The offering is expected to close on or about February 16, 2021, subject to customary closing conditions. In addition, TherapeuticsMD has granted t

TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the offering. All of the shares in the offering are to be sold by TherapeuticsMD. Cantor Fitzgerald & Co. is acting as sole bookrunning manager for the offering. TherapeuticsMD intends to use the net proceeds

TherapeuticsMD Announces Underwritten Public Offering of its Common Stock

The stock price of TherapeuticsMD Inc (NASDAQ: TXMD) is trading at over 35% pre-market. This is why it happened.

TXMD Stock Price Increases Over 35% Pre-Market: Why It Happened

The company has been burning significant cash, but the trend is finally changing. Annovera grew sales by 50% in Q3 which took the pressure off somewhat.

TherapeuticsMD: Annovera May Save The Day

AMC Entertainment

GameStop

Inovio Pharmaceuticals

American Airlines

Blink Charging

Nikola

Virgin Galactic

Tilray Brands

Workhorse Group

Pessimists have piled into these companies, but that doesn't seem to be fazing millennial investors one bit.

10 Robinhood Stocks With the Highest Short Interest

Clovis Oncology

Dynavax Technologies

Lannett Company

Cenntro Electric Group

OPKO Health

Precigen

Senseonics Holdings

United Microelectronics

VBI Vaccines

The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's known as a short squeeze.

10 Short Squeeze Candidates Under $10

Catalyst Pharmaceuticals

Now that AMC, GameStop, American Airlines and Bed, Bath & Beyond have been pushed to wild levels, well above any sane valuation, the question is which companies will be the next to be “recommended” by members of the WallStreetBets message board on Reddit and traded heavily through online brokerage firm Robinhood.

Catalyst Pharma, TherapeuticsMD May Be Next WallStreetBets Targets

TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

TherapeuticsMD (TXMD) Surges: Stock Moves 6.8% Higher

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to present at Stifel 2020 Virtual Healthcare Conference on Tuesday, Nov. 17 at 9:20 a.m. ET; see details for live webcast

TherapeuticsMD Announces Participation in the Stifel 2020 Virtual Healthcare Conference

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock for gross proceeds of $30 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by TherapeuticsMD. The offering is expected to close on or about November 12, 2020, subject to customary closing conditions. In addition, TherapeuticsMD has granted th

TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock

TherapeuticsMD's (TXMD) CEO Robert Finizio on Q3 2020 Results - Earnings Call Transcript

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 28.57% and 9.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) Reports Q3 Loss, Tops Revenue Estimates

Shares of TherapeuticsMD (NASDAQ:TXMD) moved higher by 2.5% in pre-market trading after the company reported Q3 results.

TherapeuticsMD: Q3 Earnings Insights

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD releases Q3 business and financial results; holds conference call at 8:30 am ET today

TherapeuticsMD® Announces Third Quarter 2020 Financial Results

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate TherapeuticsMD (TXMD) to Report a Decline in Earnings: What to Look Out for

News for TherapeuticsMD Stock (TXMD)